Report Detail
Global Hemophilia Drugs Market Research Report 2019
- RnM3108693 |
- 12 March, 2019 |
- Global |
- 107 Pages |
- QYResearch |
- Pharma & Healthcare
The hemophilia treatment drugs market is experiencing entry of a large number of new drugs in the market. Few of them have already arrived and other long lasting clotting factors and more promising drugs are on their way to get launched in this market. For instance, follow up data from phase I/II study of hemophilia medicine ‘Emicizumab’ by Roche has demonstrated promising results regarding safety and prophylactic efficiency in people with severe hemophilia A. Another example is of ‘Eloctate’ for type A and ‘Aprolix’ for type B hemophilia, respectively. These two newly arrived biogen products are opposed to commonly prescribe course of three infusions per week as they are longer-acting than traditional treatments and require only one to two infusions per week, due to their new mechanism of action.
With increasing attention on prophylactic treatment, the market for hemophilia drugs is estimated to have a positive outlook over the coming years. The prophylactic treatment approach prevents spontaneous bleeding episodes, significantly improves the quality of life in terms of physical activities, and maintains the level of clotting factors above a baseline. According to the studies conducted by the US National Library of Medicine determined that the savings on prophylactic treatment be approximately USD 8,312 to USD 17,675 per bleeding episode in a person. Moreover, this line of treatment reduces joint damage and suffering from pain. Several of such long-acting therapeutics are under development and expected to be launched over the next four years. The shift in preference for prophylactic treatment due to its advantages will drive this market’s growth over the forecast period.
The Americas led the global hemophilia drugs market in 2017 and is expected to continue its dominance until the end of 2023. The Americas have the highest revenue share in the global market with the US contributing to the majority of this revenue. Several countries in the region have introduced health care reforms which are having a positive impact on the market growth. Moreover, healthcare reforms in the US have also helped reduce the cost of pharmaceutical drugs, increased access to healthcare, and improved the overall quality of healthcare. These healthcare reforms are likely to have a positive impact on healthcare insurance and also reduce hospital stay and overall medical expenses, which will boost this market’s growth in the region.
The global Hemophilia Drugs market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Hemophilia Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Hemophilia Drugs market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.
The following manufacturers are covered:
Baxalta
Bayer
CSL Behring
Pfizer
Alnylam Pharmaceuticals
BioMarin
Catalyst Biosciences
Dimension Therapeutics
F. Hoffmann-La Roche
Grifols
Octapharma
Sangamo Biosciences
Spark Therapeutics
Swedish Orphan Biovitrum
Segment by Regions
North America
Europe
China
Japan
Segment by Type
Hemophilia A
Inhibitors
Hemophilia B
Von Willebrand Disease
Segment by Application
Recombinant Therapies
Plasma-Derived Therapies
Table of Contents
Executive Summary
1 Hemophilia Drugs Market Overview
- 1.1 Product Overview and Scope of Hemophilia Drugs
- 1.2 Hemophilia Drugs Segment by Type
- 1.2.1 Global Hemophilia Drugs Production Growth Rate Comparison by Type (2014-2025)
- 1.2.2 Hemophilia A
- 1.2.3 Inhibitors
- 1.2.4 Hemophilia B
- 1.2.5 Von Willebrand Disease
- 1.3 Hemophilia Drugs Segment by Application
- 1.3.1 Hemophilia Drugs Consumption Comparison by Application (2014-2025)
- 1.3.2 Recombinant Therapies
- 1.3.3 Plasma-Derived Therapies
- 1.4 Global Hemophilia Drugs Market by Region
- 1.4.1 Global Hemophilia Drugs Market Size Region
- 1.4.2 North America Status and Prospect (2014-2025)
- 1.4.3 Europe Status and Prospect (2014-2025)
- 1.4.4 China Status and Prospect (2014-2025)
- 1.4.5 Japan Status and Prospect (2014-2025)
- 1.5 Global Hemophilia Drugs Market Size
- 1.5.1 Global Hemophilia Drugs Revenue (2014-2025)
- 1.5.2 Global Hemophilia Drugs Production (2014-2025)
2 Global Hemophilia Drugs Market Competition by Manufacturers
- 2.1 Global Hemophilia Drugs Production Market Share by Manufacturers (2014-2019)
- 2.2 Global Hemophilia Drugs Revenue Share by Manufacturers (2014-2019)
- 2.3 Global Hemophilia Drugs Average Price by Manufacturers (2014-2019)
- 2.4 Manufacturers Hemophilia Drugs Production Sites, Area Served, Product Types
- 2.5 Hemophilia Drugs Market Competitive Situation and Trends
- 2.5.1 Hemophilia Drugs Market Concentration Rate
- 2.5.2 Hemophilia Drugs Market Share of Top 3 and Top 5 Manufacturers
- 2.5.3 Mergers & Acquisitions, Expansion
3 Global Hemophilia Drugs Production Market Share by Regions
- 3.1 Global Hemophilia Drugs Production Market Share by Regions
- 3.2 Global Hemophilia Drugs Revenue Market Share by Regions (2014-2019)
- 3.3 Global Hemophilia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 3.4 North America Hemophilia Drugs Production
- 3.4.1 North America Hemophilia Drugs Production Growth Rate (2014-2019)
- 3.4.2 North America Hemophilia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 3.5 Europe Hemophilia Drugs Production
- 3.5.1 Europe Hemophilia Drugs Production Growth Rate (2014-2019)
- 3.5.2 Europe Hemophilia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 3.6 China Hemophilia Drugs Production (2014-2019)
- 3.6.1 China Hemophilia Drugs Production Growth Rate (2014-2019)
- 3.6.2 China Hemophilia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 3.7 Japan Hemophilia Drugs Production (2014-2019)
- 3.7.1 Japan Hemophilia Drugs Production Growth Rate (2014-2019)
- 3.7.2 Japan Hemophilia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
4 Global Hemophilia Drugs Consumption by Regions
- 4.1 Global Hemophilia Drugs Consumption by Regions
- 4.2 North America Hemophilia Drugs Consumption (2014-2019)
- 4.3 Europe Hemophilia Drugs Consumption (2014-2019)
- 4.4 China Hemophilia Drugs Consumption (2014-2019)
- 4.5 Japan Hemophilia Drugs Consumption (2014-2019)
5 Global Hemophilia Drugs Production, Revenue, Price Trend by Type
- 5.1 Global Hemophilia Drugs Production Market Share by Type (2014-2019)
- 5.2 Global Hemophilia Drugs Revenue Market Share by Type (2014-2019)
- 5.3 Global Hemophilia Drugs Price by Type (2014-2019)
- 5.4 Global Hemophilia Drugs Production Growth by Type (2014-2019)
6 Global Hemophilia Drugs Market Analysis by Applications
- 6.1 Global Hemophilia Drugs Consumption Market Share by Application (2014-2019)
- 6.2 Global Hemophilia Drugs Consumption Growth Rate by Application (2014-2019)
7 Company Profiles and Key Figures in Hemophilia Drugs Business
- 7.1 Baxalta
- 7.1.1 Baxalta Hemophilia Drugs Production Sites and Area Served
- 7.1.2 Hemophilia Drugs Product Introduction, Application and Specification
- 7.1.3 Baxalta Hemophilia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 7.1.4 Main Business and Markets Served
- 7.2 Bayer
- 7.2.1 Bayer Hemophilia Drugs Production Sites and Area Served
- 7.2.2 Hemophilia Drugs Product Introduction, Application and Specification
- 7.2.3 Bayer Hemophilia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 7.2.4 Main Business and Markets Served
- 7.3 CSL Behring
- 7.3.1 CSL Behring Hemophilia Drugs Production Sites and Area Served
- 7.3.2 Hemophilia Drugs Product Introduction, Application and Specification
- 7.3.3 CSL Behring Hemophilia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 7.3.4 Main Business and Markets Served
- 7.4 Pfizer
- 7.4.1 Pfizer Hemophilia Drugs Production Sites and Area Served
- 7.4.2 Hemophilia Drugs Product Introduction, Application and Specification
- 7.4.3 Pfizer Hemophilia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 7.4.4 Main Business and Markets Served
- 7.5 Alnylam Pharmaceuticals
- 7.5.1 Alnylam Pharmaceuticals Hemophilia Drugs Production Sites and Area Served
- 7.5.2 Hemophilia Drugs Product Introduction, Application and Specification
- 7.5.3 Alnylam Pharmaceuticals Hemophilia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 7.5.4 Main Business and Markets Served
- 7.6 BioMarin
- 7.6.1 BioMarin Hemophilia Drugs Production Sites and Area Served
- 7.6.2 Hemophilia Drugs Product Introduction, Application and Specification
- 7.6.3 BioMarin Hemophilia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 7.6.4 Main Business and Markets Served
- 7.7 Catalyst Biosciences
- 7.7.1 Catalyst Biosciences Hemophilia Drugs Production Sites and Area Served
- 7.7.2 Hemophilia Drugs Product Introduction, Application and Specification
- 7.7.3 Catalyst Biosciences Hemophilia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 7.7.4 Main Business and Markets Served
- 7.8 Dimension Therapeutics
- 7.8.1 Dimension Therapeutics Hemophilia Drugs Production Sites and Area Served
- 7.8.2 Hemophilia Drugs Product Introduction, Application and Specification
- 7.8.3 Dimension Therapeutics Hemophilia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 7.8.4 Main Business and Markets Served
- 7.9 F. Hoffmann-La Roche
- 7.9.1 F. Hoffmann-La Roche Hemophilia Drugs Production Sites and Area Served
- 7.9.2 Hemophilia Drugs Product Introduction, Application and Specification
- 7.9.3 F. Hoffmann-La Roche Hemophilia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 7.9.4 Main Business and Markets Served
- 7.10 Grifols
- 7.10.1 Grifols Hemophilia Drugs Production Sites and Area Served
- 7.10.2 Hemophilia Drugs Product Introduction, Application and Specification
- 7.10.3 Grifols Hemophilia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 7.10.4 Main Business and Markets Served
- 7.11 Octapharma
- 7.12 Sangamo Biosciences
- 7.13 Spark Therapeutics
- 7.14 Swedish Orphan Biovitrum
8 Hemophilia Drugs Manufacturing Cost Analysis
- 8.1 Hemophilia Drugs Key Raw Materials Analysis
- 8.1.1 Key Raw Materials
- 8.1.2 Price Trend of Key Raw Materials
- 8.1.3 Key Suppliers of Raw Materials
- 8.2 Proportion of Manufacturing Cost Structure
- 8.3 Manufacturing Process Analysis of Hemophilia Drugs
- 8.4 Hemophilia Drugs Industrial Chain Analysis
9 Marketing Channel, Distributors and Customers
- 9.1 Marketing Channel
- 9.1.1 Direct Marketing
- 9.1.2 Indirect Marketing
- 9.2 Hemophilia Drugs Distributors List
- 9.3 Hemophilia Drugs Customers
10 Market Dynamics
- 10.1 Market Trends
- 10.2 Opportunities
- 10.3 Market Drivers
- 10.4 Challenges
- 10.5 Influence Factors
11 Global Hemophilia Drugs Market Forecast
- 11.1 Global Hemophilia Drugs Production, Revenue Forecast
- 11.1.1 Global Hemophilia Drugs Production Growth Rate Forecast (2019-2025)
- 11.1.2 Global Hemophilia Drugs Revenue and Growth Rate Forecast (2019-2025)
- 11.1.3 Global Hemophilia Drugs Price and Trend Forecast (2019-2025)
- 11.2 Global Hemophilia Drugs Production Forecast by Regions (2019-2025)
- 11.2.1 North America Hemophilia Drugs Production, Revenue Forecast (2019-2025)
- 11.2.2 Europe Hemophilia Drugs Production, Revenue Forecast (2019-2025)
- 11.2.3 China Hemophilia Drugs Production, Revenue Forecast (2019-2025)
- 11.2.4 Japan Hemophilia Drugs Production, Revenue Forecast (2019-2025)
- 11.3 Global Hemophilia Drugs Consumption Forecast by Regions (2019-2025)
- 11.3.1 North America Hemophilia Drugs Consumption Forecast (2019-2025)
- 11.3.2 Europe Hemophilia Drugs Consumption Forecast (2019-2025)
- 11.3.3 China Hemophilia Drugs Consumption Forecast (2019-2025)
- 11.3.4 Japan Hemophilia Drugs Consumption Forecast (2019-2025)
- 11.4 Global Hemophilia Drugs Production, Revenue and Price Forecast by Type (2019-2025)
- 11.5 Global Hemophilia Drugs Consumption Forecast by Application (2019-2025)
12 Research Findings and Conclusion
13 Methodology and Data Source
- 13.1 Methodology/Research Approach
- 13.1.1 Research Programs/Design
- 13.1.2 Market Size Estimation
- 13.1.3 Market Breakdown and Data Triangulation
- 13.2 Data Source
- 13.2.1 Secondary Sources
- 13.2.2 Primary Sources
- 13.3 Author List
Summary:
Get latest Market Research Reports on Hemophilia Drugs. Industry analysis & Market Report on Hemophilia Drugs is a syndicated market report, published as Global Hemophilia Drugs Market Research Report 2019. It is complete Research Study and Industry Analysis of Hemophilia Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
